These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35927042)

  • 1. [Improving the management of chronic
    She DY
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):733-735. PubMed ID: 35927042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chinese expert consensus on the management of lower respiratory tract infections of
    Pulmonary Infection Assembly of Chinese Thoracic Society
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.
    Wilson R; Aksamit T; Aliberti S; De Soyza A; Elborn JS; Goeminne P; Hill AT; Menendez R; Polverino E
    Respir Med; 2016 Aug; 117():179-89. PubMed ID: 27492530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa infection in cystic fibrosis: prevent, eradicate or both?
    Eber E; Zach MS
    Thorax; 2010 Oct; 65(10):849-51. PubMed ID: 20861286
    [No Abstract]   [Full Text] [Related]  

  • 7. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.
    Høiby N; Koch C
    Thorax; 1990 Nov; 45(11):881-4. PubMed ID: 2256020
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
    Ratjen F
    Int J Antimicrob Agents; 2001 Feb; 17(2):93-6. PubMed ID: 11165111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
    Langan KM; Kotsimbos T; Peleg AY
    Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriology and treatment of infections in the upper and lower airways in patients with primary ciliary dyskinesia: adressing the paranasal sinuses.
    Alanin MC
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination against respiratory Pseudomonas aeruginosa infection.
    Grimwood K; Kyd JM; Owen SJ; Massa HM; Cripps AW
    Hum Vaccin Immunother; 2015; 11(1):14-20. PubMed ID: 25483510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
    BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of non-cystic fibrosis bronchiectasis.
    Webb P; King J; Baxter C; Lord RW
    Br J Hosp Med (Lond); 2021 Jul; 82(7):1-9. PubMed ID: 34338026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis.
    Hoiby N; Flensborg EW; Beck B; Friis B; Jacobsen SV; Jacobsen L
    Scand J Respir Dis; 1977 Apr; 58(2):65-79. PubMed ID: 404701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.